Latest News and Press Releases

Preclinical data highlight MTHFD2 as a promising metabolic target in autoimmune disease, providing strong validation for the advancement of SIT-047, Sitryx’s MTHFD2 inhibitor program, into clinical...

Novel, oral candidate with first-in-class potential progresses to regulatory non-clinical studies to support a Clinical Trial Authorisation First indication will be psoriatic arthritis, a...

Sitryx initiates Phase 1 clinical trial of potential disease-modifying treatment for atopic dermatitis SYX-5219 SYX-5219 is a first-in-class oral PKM2 modulator designed to drive sustained disease...

Sitryx announces leadership transition Iain Kilty appointed Chief Executive Officer Neil Weir to assume role of President and remain on Board of Directors Oxford, UK – 2 July 2024 – Sitryx...

Sitryx announces collaboration partner Lilly has commenced a Phase 1 study of SIT-011 for chronic autoimmune and inflammatory diseases Milestone triggers double-digit million dollar payment to...

New biopharmaceutical company Sitryx launches with $30 million fundraising to develop disease modifying therapeutics in immunometabolism Fast-emerging area of research with potential to treat severe...

New biopharmaceutical company Sitryx launches with $30 million fundraising to develop disease modifying therapeutics in immunometabolism Fast-emerging area of research with potential to treat severe...